Back to results
US 6,656,466 B1Granted
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
AssigneeGenetech, Inc.
InventorsTina Etcheverry, Thomas Ryll
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGenetech, Inc.
InventorsTina Etcheverry, Thomas Ryll
Estimating the term…
The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.
A human TNFR1-IgG1 preparation comprising TNFR1-IgG1 prepared by a process comprising:
A therapeutic composition comprising human TNFR1-IgG1 prepared by a process comprising:
A human TNFR1-IgG1 preparation comprising human TNFR1-IgG1 molecules wherein the TNFR1-IgG1 molecules have a molar ratio of sialic acid to protein of about 4-7.
A human TNFR1-IgG1 preparation comprising human TNFR1-IgG1 molecules wherein the TNFR1-IgG1 molecules have about 1-2 moles of exposed N-acetylglucosamine residues per mole of TNFR1-IgG1 protein.
A human TNFR1-IgG1 preparation comprising human TNFR1-IgG1 molecules wherein the TNFR1-IgG1 molecules have a molar ratio of sialic acid to N-acetylglucosamine of about 0.35 to about 0.5.
Dependencies are inferred from the claim text.